東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Generation of chimeric antigen recep...

Kloss, Christopher Carl.

FindBook

Google Book

Amazon

博客來

Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice./
作者:	Kloss, Christopher Carl.
面頁冊數:	150 p.
附註:	Source: Dissertation Abstracts International, Volume: 74-11(E), Section: B.
Contained By:	Dissertation Abstracts International74-11B(E).
標題:	Chemistry, Inorganic. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3572400
ISBN:	9781303310997

Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice.
Kloss, Christopher Carl.

Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice. - 150 p.

Source: Dissertation Abstracts International, Volume: 74-11(E), Section: B.

Thesis (Ph.D.)--Weill Medical College of Cornell University, 2013.

Cancers remain difficult to treat due to heterogeneity of the cancer cells themselves as well as the diversity of cells that contribute to the environment in which the cancer grows. Success in eliminating these aberrant cells can be achieved upon recognition of the cancerous cells by sufficiently activated cytotoxic T cells. However, the environment containing the tumor uses many different mechanisms to ensure a highly immunosuppressive environment, therefore inhibiting any T cells that could react. By using retroviral vectors for expression of Chimeric Antigen Receptors in T cells, we can induce sufficient T cell signaling upon encountering an antigen of choice. By targeting antigens expressed by cancerous cells, these genetically engineered T cells can receive sufficient signaling and mount a robust T cell mediated illumine response to eliminate tumor. However, it is difficult to select a single antigen with specificity for the cancerous cells and not for normal cells. Therefore, we attempted to split T cell activation and co-stimulation signals by supplying CD3zeta activation signals upon binding of one antigen by one receptor and supplying co-stimulation signals CD28 and 4-1BB upon binding of a second antigen by an additional receptor. By splitting the induction of these signaling pathways, we can successfully supply all three signals upon binding both antigens. Depending on the strength of the CD3zeta activation signal supplied, carefully titered cytotoxicity and cytokine secretion can be achieved. This allows for the selective eradication of cancerous cells expressing both antigens, but reduces any immune response to cells expressing either antigen alone. Attempts were made to use human embryonic stem cells to generate mature T cells. We used fluorescent reporters for live imaging of these cells in order to determine how these cells develop to give rise to hematopoietic lineages. We discovered that only embryonic and fetal types of hematopoietic cells were generated with an inability to produce mature T cells with current technology. By using mature T cells and by supplying sufficient T cell signaling upon binding a combination of antigens, we demonstrate the ability to generate potent T cell mediated immune responses against cancerous cells expressing two antigens.

ISBN: 9781303310997Subjects--Topical Terms:

517253
Chemistry, Inorganic.

Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice.
LDR:03298nam a2200289 4500 001 1963644
005 20141007080159.5
008 150210s2013 ||||||||||||||||| ||eng d
020 $a 9781303310997
035 $a (MiAaPQ)AAI3572400
035 $a AAI3572400
040 $a MiAaPQ $c MiAaPQ
100 1 $a Kloss, Christopher Carl. $3 2099943
245 1 0 $a Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice.
300 $a 150 p.
500 $a Source: Dissertation Abstracts International, Volume: 74-11(E), Section: B.
500 $a Adviser: Michel Sadelcuh.
502 $a Thesis (Ph.D.)--Weill Medical College of Cornell University, 2013.
520 $a Cancers remain difficult to treat due to heterogeneity of the cancer cells themselves as well as the diversity of cells that contribute to the environment in which the cancer grows. Success in eliminating these aberrant cells can be achieved upon recognition of the cancerous cells by sufficiently activated cytotoxic T cells. However, the environment containing the tumor uses many different mechanisms to ensure a highly immunosuppressive environment, therefore inhibiting any T cells that could react. By using retroviral vectors for expression of Chimeric Antigen Receptors in T cells, we can induce sufficient T cell signaling upon encountering an antigen of choice. By targeting antigens expressed by cancerous cells, these genetically engineered T cells can receive sufficient signaling and mount a robust T cell mediated illumine response to eliminate tumor. However, it is difficult to select a single antigen with specificity for the cancerous cells and not for normal cells. Therefore, we attempted to split T cell activation and co-stimulation signals by supplying CD3zeta activation signals upon binding of one antigen by one receptor and supplying co-stimulation signals CD28 and 4-1BB upon binding of a second antigen by an additional receptor. By splitting the induction of these signaling pathways, we can successfully supply all three signals upon binding both antigens. Depending on the strength of the CD3zeta activation signal supplied, carefully titered cytotoxicity and cytokine secretion can be achieved. This allows for the selective eradication of cancerous cells expressing both antigens, but reduces any immune response to cells expressing either antigen alone. Attempts were made to use human embryonic stem cells to generate mature T cells. We used fluorescent reporters for live imaging of these cells in order to determine how these cells develop to give rise to hematopoietic lineages. We discovered that only embryonic and fetal types of hematopoietic cells were generated with an inability to produce mature T cells with current technology. By using mature T cells and by supplying sufficient T cell signaling upon binding a combination of antigens, we demonstrate the ability to generate potent T cell mediated immune responses against cancerous cells expressing two antigens.
590 $a School code: 0967.
650 4 $a Chemistry, Inorganic. $3 517253
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Engineering, Biomedical. $3 1017684
690 $a 0488
690 $a 0992
690 $a 0541
710 2 $a Weill Medical College of Cornell University. $3 1021736
773 0 $t Dissertation Abstracts International $g 74-11B(E).
790 $a 0967
791 $a Ph.D.
792 $a 2013
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3572400